Literature DB >> 20624959

Blocking IL-1beta to slow down progression of ALS?

Jos W M van der Meer1, Anna Simon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20624959      PMCID： PMC2919971          DOI： 10.1073/pnas.1007946107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  12 in total

1.  Inhibition of ICE slows ALS in mice.

Authors:  R M Friedlander; R H Brown; V Gagliardini; J Wang; J Yuan
Journal:  Nature       Date:  1997-07-03       Impact factor: 49.962

2.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

3.  Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis.

Authors:  Felix Meissner; Kaaweh Molawi; Arturo Zychlinsky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

4.  Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra).

Authors:  E J Bodar; A Simon; M de Visser; J W M van der Meer
Journal:  Neth J Med       Date:  2009-10       Impact factor: 1.422

5.  Interleukin-1 system in CNS stress: seizures, fever, and neurotrauma.

Authors:  Tamas Bartfai; Manuel Sanchez-Alavez; Siv Andell-Jonsson; Marianne Schultzberg; Annamaria Vezzani; Erik Danielsson; Bruno Conti
Journal:  Ann N Y Acad Sci       Date:  2007-07-26       Impact factor: 5.691

Review 6.  Current hypotheses for the underlying biology of amyotrophic lateral sclerosis.

Authors:  Jeffrey D Rothstein
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

Review 7.  Immunological and inflammatory functions of the interleukin-1 family.

Authors:  Charles A Dinarello
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

Review 8.  Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*).

Authors:  Seth L Masters; Anna Simon; Ivona Aksentijevich; Daniel L Kastner
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

9.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.

Authors:  Raphaela Goldbach-Mansky; Natalie J Dailey; Scott W Canna; Ana Gelabert; Janet Jones; Benjamin I Rubin; H Jeffrey Kim; Carmen Brewer; Christopher Zalewski; Edythe Wiggs; Suvimol Hill; Maria L Turner; Barbara I Karp; Ivona Aksentijevich; Frank Pucino; Scott R Penzak; Margje H Haverkamp; Leonard Stein; Barbara S Adams; Terry L Moore; Robert C Fuhlbrigge; Bracha Shaham; James N Jarvis; Kathleen O'Neil; Richard K Vehe; Laurie O Beitz; Gregory Gardner; William P Hannan; Robert W Warren; William Horn; Joe L Cole; Scott M Paul; Philip N Hawkins; Tuyet Hang Pham; Christopher Snyder; Robert A Wesley; Steven C Hoffmann; Steven M Holland; John A Butman; Daniel L Kastner
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

10.  Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage.

Authors:  Ivelina Gueorguieva; Simon R Clark; Catherine J McMahon; Sylvia Scarth; Nancy J Rothwell; Pippa J Tyrrell; Pippa J Tyrell; Stephen J Hopkins; Malcolm Rowland
Journal:  Br J Clin Pharmacol       Date:  2007-09-13       Impact factor: 4.335
View more
  7 in total

1.  Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.

Authors:  Charles A Dinarello; Gianluca Fossati; Paolo Mascagni
Journal:  Mol Med       Date:  2011-05-05       Impact factor: 6.354

Review 2.  Neurodegenerative Disease and the NLRP3 Inflammasome.

Authors:  Jonathan A Holbrook; Heledd H Jarosz-Griffiths; Emily Caseley; Samuel Lara-Reyna; James A Poulter; Caroline H Williams-Gray; Daniel Peckham; Michael F McDermott
Journal:  Front Pharmacol       Date:  2021-03-10       Impact factor: 5.810

Review 3.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 4.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Authors:  Charles A Dinarello; Anna Simon; Jos W M van der Meer
Journal:  Nat Rev Drug Discov       Date:  2012-08       Impact factor: 84.694

5.  Humoral factors in ALS patients during disease progression.

Authors:  Jared Ehrhart; Adam J Smith; Nicole Kuzmin-Nichols; Theresa A Zesiewicz; Israt Jahan; R Douglas Shytle; Seol-Hee Kim; Cyndy D Sanberg; Tuan H Vu; Clifton L Gooch; Paul R Sanberg; Svitlana Garbuzova-Davis
Journal:  J Neuroinflammation       Date:  2015-06-28       Impact factor: 8.322

6.  Elucidation of Relevant Neuroinflammation Mechanisms Using Gene Expression Profiling in Patients with Amyotrophic Lateral Sclerosis.

Authors:  Yu Hui Won; Min-Young Lee; Young-Chul Choi; Yoon Ha; Hyongbum Kim; Do-Young Kim; Myung-Sun Kim; Ji Hea Yu; Jung Hwa Seo; MinGi Kim; Sung-Rae Cho; Seong-Woong Kang
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

Review 7.  The Therapeutic Prospects of Targeting IL-1R1 for the Modulation of Neuroinflammation in Central Nervous System Disorders.

Authors:  João P Luís; Carlos J V Simões; Rui M M Brito
Journal:  Int J Mol Sci       Date:  2022-02-02       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.